Verus Capital Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.6M Sell
53,144
-2,462
-4% -$546K 0.79% 29
2025
Q4
$12.7M Sell
55,606
-925
-2% -$211K 0.85% 20
2025
Q3
$13.1M Sell
56,531
-1,340
-2% -$273K 1.02% 17
2025
Q2
$10.7M Sell
57,871
-905
-2% -$168K 0.96% 18
2025
Q1
$12.3M Sell
58,776
-2,109
-3% -$410K 1.23% 13
2024
Q4
$10.8M Sell
60,885
-1,087
-2% -$200K 1.03% 15
2024
Q3
$12.2M Sell
61,972
-629
-1% -$117K 1.19% 14
2024
Q2
$10.7M Sell
62,601
-2,039
-3% -$338K 1.11% 15
2024
Q1
$11.8M Buy
64,640
+990
+2% +$171K 1.3% 13
2023
Q4
$9.86M Sell
63,650
-1,445
-2% -$211K 1.21% 16
2023
Q3
$9.7M Sell
65,095
-11,540
-15% -$1.69M 1.35% 12
2023
Q2
$10.3M Sell
76,635
-12,402
-14% -$1.82M 1.46% 11
2023
Q1
$14.2M Buy
89,037
+6,300
+8% +$963K 2.22% 8
2022
Q4
$13.4M Sell
82,737
-5,043
-6% -$773K 2.51% 8
2022
Q3
$11.8M Buy
87,780
+24,606
+39% +$3.53M 2.22% 8
2022
Q2
$14.6M Sell
63,174
-34,590
-35% -$5.29M 2.86% 6
2022
Q1
$15M Buy
+97,764
New +$14.2M 2.33% 7
2020
Q1
$1.54M Buy
20,282
+3,758
+23% +$320K 0.49% 38
2019
Q4
$1.46M Buy
+16,524
New +$1.37M 0.48% 35

Other funds holding ABBV

Verus Capital Partners's ABBV Position: Q1 2026 in Review

Verus Capital Partners reduced its AbbVie (ABBV) stake by 4.4% in Q1 2026, selling an estimated $546K and leaving 53,144 shares worth $11.6M. The position accounts for 0.79% of the portfolio, ranked #29.

Verus Capital Partners first reported a position in ABBV in Q4 2019 and has held it in 19 quarters since. The position peaked at $15M in Q1 2022. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Verus Capital Partners held 53,144 shares of AbbVie worth $11.6M as of Q1 2026.
  • Verus Capital Partners sold 2,462 AbbVie shares in Q1 2026, an estimated $546K.
  • AbbVie made up 0.79% of Verus Capital Partners's portfolio in Q1 2026, its #29 holding.
  • Verus Capital Partners first reported a position in AbbVie in Q4 2019 and has held it in 19 quarters since.
  • Verus Capital Partners's AbbVie position peaked at $15M in Q1 2022.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Verus Capital Partners's 13F filing for Q1 2026, filed 22 May 2026.